期刊文献+

不同原发部位弥漫大B细胞淋巴瘤临床病理特点及预后比较 被引量:8

Comparison of clinical-pathological characteristics and prognosis of diffuse large B-cell lymphoma from different origins
原文传递
导出
摘要 目的 比较原发结外与结内弥漫大B细胞淋巴瘤(DLBCL)患者的临床病理特点及预后方面的差异.方法 回顾分析2007年1月至2012年12月134例DLBCL患者的临床病理特征及治疗疗效.结果 DLBCL 134例,占同期收治非霍奇金淋巴瘤(NHL)的52.14%(134/257),结外DLBCL共93例占总体DLBCL的69.4%.结外DLBCL分期为Ⅲ~Ⅳ期者占55.9%(52/93),结内DLBCL中Ⅲ~Ⅳ期者占75.6%(31/41),差异有统计学意义(P=0.035).结外DLBCL中乳酸脱氢酶升高者占33.3%(31/93),而结内DLBCL中升高者占58.5%(24/41),差异有统计学意义(P=0.008).其他临床特征如出现B症状、大肿块、骨髓浸润、红细胞沉降率升高的比例及美国东部肿瘤协作组(ECOG)评分、国际预后指数(IPI)评分差异均无统计学意义(均P>0.05).结外与结内DLBCL生发中心及非生发中心起源出现的比例差异无统计学意义(P=0.623).结外与结内DLBCL的3年总生存率分别为73.2%、55.2%,3年疾病无进展生存率分别为46.3%、44.1%,差异均无统计学意义(P值分别为0.065、0.748).结论 原发结外DLBCL的发病率较高,与结内DLBCL相比其临床分期较早,肿瘤负荷较低,但两者的免疫表型、分化特征及预后无明显差异. Objective To evaluate the difference between nodal and extra-nodal diffuse large B-cell lymphoma (DLBCL) in clinical-pathological feature and prognosis.Methods The clinical data of 134 cases of DLBCL patients were reviewed and analyzed.Results The DLBCL patients accounted for 52.14 % (134/257) of non-Hodgkin lymphoma of the same period and the extra-nodal DLBCL patients accounted for 69.4 %.The proportion of stage Ⅲ/Ⅳ disease in extra-nodal DLBCL and nodal DLBCL were 55.9 % (52/93) and 75.6 %(31/41),respectively.Elevated LDH was reported in 33.3 % (31/93) of extra-nodal DLBCL and 58.5 % (24/41)of nodal DLBCL Other clinical characteristics such as B symptoms,bulky disease,elevated ESR,ECOG scores and IPI scores were not significantly different between these two groups (all P > 0.05).No difference in the frequency of GCB and non-GCB subtypes was observed between extra-nodal and nodal DLBCL (P =0.623).The 3-year overall survival rates and 3-year progression free survival rates for extra-nodal and nodal DLBCL were 73.2 %,55.2 % (P =0.065) and 46.3 %,44.1% (P =0.748).Conclusions The morbidity of extranodal DLBCL is high.Primary extra-nodal DLBCL patients present early-stage disease and normal LDH more frequently than the nodal DLBCL,while no significant difference in the frequency of pathological subtypes and 3-year OS and PFS is observed between these two groups.
出处 《白血病.淋巴瘤》 CAS 2014年第4期208-212,共5页 Journal of Leukemia & Lymphoma
基金 吉林省重点科技攻关项目(20130206024SF)
关键词 淋巴瘤 大B细胞 弥漫型 原发部位 临床特点 病理分型 预后 Lymphoma, large B-cell, diffuse Primary site Clinical characteristic Pathological subtype Prognosis
  • 相关文献

参考文献27

  • 1Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)[J]. Blood, 2007, 110: 695-708.
  • 2A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project[J]. Blood, 1997, 89:3909-3918.
  • 3Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group[J]. Blood, 1994, 84: 1361-1392.
  • 4Pileri SA, Dimhofer S, Went P, et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassifieation[J]. Histopathol, 2002, 41:482-509.
  • 5Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--AMie House, Virginia, November, 1997[J]. Hematol J, 2000, 1: 53-66.
  • 6Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non- Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas[J]. Ann Oncol, 1997, 8: 727-737.
  • 7Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non- Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites[J]. Ann Oncol, 1999, 10: 1023-1033.
  • 8Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases [J]. Br J Haematol, 2004, 124: 151-159.
  • 9Zucca E, Cavalli F. Extranodal lymphomas[J]. Ann Oncol, 2000, 11 Suppl 3: 219-222.
  • 10Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995[J]. J Natl Cancer Inst, 2000, 92: 1240-1251.

二级参考文献79

  • 1卢红阳,蔡菊芬,余新民,顾怡生.274例原发性结外型淋巴瘤临床分析[J].白血病.淋巴瘤,2004,13(5):293-294. 被引量:10
  • 2荆凌华,刘松年.原发性结外淋巴瘤43例分析[J].中国误诊学杂志,2005,5(2):339-340. 被引量:2
  • 3The Non-Hodgkin's Lymphoma Classification Project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood,1997,89:3909-3918.
  • 4Mфller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma : clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br J Haematol, 2004,124 : 151-159.
  • 5Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large Bcell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Onco1,2005,23:2797-2804.
  • 6Shipp MA,Harrington DP, Anderson JR,et al. A predictive model for aggressive non - Hodgkin's lymphoma. N Engl J Med , 1993 ,329:987-994.
  • 7Mok TS,Steinberg J,Chan AT, et al. Application of the international prognostic index in a study of Chinese patients with nonHodgkin's lymphoma and a high incidence of primary extranodal lymphoma. Cancer, 1998,82:2439-2448.
  • 8Gavrilovic IT, Hormign A,Yahalom J,et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary cns lymphoma. J Clin Oncol ,2006,24:4570-4574.
  • 9Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann 0ncol,2008,19:233-241.
  • 10Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Onco1,2003,21:20-27.

共引文献87

同被引文献44

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部